


PG4894USW

## In the Claims:

1. (Previously Presented) A compound of formula (I)



or a pharmaceutically acceptable salt thereof in which:

X is selected from the group consisting of oxygen or NR<sup>2</sup>;

R<sup>1</sup> is selected from the group consisting of H, C<sub>1-6</sub>alkyl, C<sub>1-2</sub>alkyl substituted by one to five fluorine atoms, C<sub>3-6</sub>alkenyl, C<sub>3-6</sub>alkynyl, C<sub>3-10</sub>cycloalkylC<sub>0-6</sub>alkyl, C<sub>4-12</sub>bridged cycloalkyl, A(CR<sup>5</sup>R<sup>6</sup>)<sub>n</sub> and B(CR<sup>5</sup>R<sup>6</sup>)<sub>n</sub>;

R<sup>2</sup> is selected from the group consisting of H and C<sub>1-6</sub>alkyl;

R<sup>3</sup> is C<sub>1-2</sub>alkyl substituted by one to five fluorine atoms;


R<sup>4</sup> is selected from the group consisting of C<sub>1-6</sub>alkyl, NH<sub>2</sub> and R<sup>8</sup>CONH;

R<sup>5</sup> and R<sup>6</sup> are independently selected from H or C<sub>1-6</sub>alkyl;

A is an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more R<sup>7</sup>;

R<sup>7</sup> is selected from the group consisting of halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl substituted by one more fluorine atoms, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkoxy substituted by one or more F, NH<sub>2</sub>SO<sub>2</sub> and C<sub>1-6</sub>alkylSO<sub>2</sub>;

B is selected from the group consisting of



) defines the point of attachment of the ring;


R<sup>8</sup> is selected from the group consisting of H, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylIOC<sub>1-6</sub>alkyl, phenyl, HO<sub>2</sub>CC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylOCOC<sub>1-6</sub>alkyl,

PG4894USW

$C_{1-6}$ alkyloCO,  $H_2NC_{1-6}$ alkyl,  $C_{1-6}$ alkyloCONHC $_{1-6}$ alkyl and  
 $C_{1-6}$ alkylCONHC $_{1-6}$ alkyl; and

n is 0 to 4,

wherein the 5-membered heteroaryl is selected from




and

wherein the 6-membered heteroaryl is selected from



2. (Previously Presented) A compound of formula (IA)



or a pharmaceutically acceptable salt thereof in which:

$R^2$  is selected from the group consisting of H and  $C_{1-6}$ alkyl;

$R^4$  is selected from the group consisting of  $C_{1-6}$ alkyl,  $NH_2$  and  $R^8CONH$ ;

$R^5$  and  $R^6$  are independently selected from H or  $C_{1-6}$ alkyl;

A is  $C_{5-7}$ cycloalkyl or an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more  $R^7$ ;


PG4894USW

$R^7$  is selected from the group consisting of halogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyl substituted by one more fluorine atoms,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkoxy substituted by one or more F,  $NH_2SO_2$  and  $C_{1-6}$ alkyl $SO_2$ ;

$R^8$  is selected from the group consisting of H,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkyl $OC_{1-6}$ alkyl, phenyl,  $HO_2CC_{1-6}$ alkyl,  $C_{1-6}$ alkyl $OCOC_{1-6}$ alkyl,  $C_{1-6}$ alkyl $OCO$ ,  $H_2NC_{1-6}$ alkyl,  $C_{1-6}$ alkyl $OCONHC_{1-6}$ alkyl and  $C_{1-6}$ alkyl $CONHC_{1-6}$ alkyl; and


n is 0 to 4,

wherein the 5-membered heteroaryl is selected from



and


wherein the 6-membered heteroaryl is selected from



3. (Previously Presented) A compound as claimed in claim 1 wherein  $R^2$  is H or methyl.
4. (Previously Presented) A compound as claimed in claim 1 wherein  $R^4$  is  $C_{1-3}$ alkyl.
5. (Previously Presented) A compound as claimed in claim 1 wherein  $R^5$  and  $R^6$  are both H.

PG4894USW

6. (Previously Presented) A compound as claimed in claim 1 wherein A is selected from the group consisting of C<sub>5-7</sub>-cycloalkyl or



) defines the point of attachment of the ring

and A is unsubstituted or substituted by one or two R<sup>7</sup>.

7. (Previously Presented) A compound as claimed in claim 1 wherein R<sup>7</sup> is selected from the group consisting of halogen, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl substituted by one to three fluorine atoms, and C<sub>1-3</sub>alkoxy.

8. (Previously Presented) A compound as claimed in claim 1 wherein R<sup>8</sup> is selected from the group consisting of C<sub>1-6</sub>alkyl, phenyl and aminomethyl.

9. (Previously Presented) A compound as claimed in claim 1 wherein n is 0 to 2.


10. (Canceled)

11. (Previously Presented) [4-(5-Methanesulfonyl-pyridin-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-methyl-(6-methyl-pyridin-2-ylmethyl)-amine;  
benzyl-[4-(5-methanesulfonyl-pyridin-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-amine;  
and  
cyclohexyl-[4-(5-methanesulfonyl-pyridin-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-amine.

PG4894USW

12. (Currently Amended) A process for the preparation of a compound as defined in claim 1, which comprises:

~~(A)~~, reacting a compound  $R^1XH$  or a protected derivative thereof with a compound of formula (III)



wherein  $R_3$  and  $R_4$  are as defined in claim 1, to produce a compound of formula (I)


and thereafter and if necessary,

~~(B)~~, interconverting the compound of formula (I) into another compound of formula (I); and/or

~~(C)~~, deprotecting the a protected derivative of compound of formula (I).

13. (Currently Amended) A process for the preparation of a compound as defined in claim 2, which comprises:

~~(A)~~ reacting an amine  $HNR^2(CR^5R^6)_nA$  or a protected derivative thereof with a compound of formula (III) wherein  $R^3$  is  $CF_3$



wherein  $R_4$  is as defined in claim 2, to produce a compound of formula (IA), and thereafter and if necessary,

~~(B)~~, interconverting the compound of formula (IA) into another compound of formula (IA); and/or

~~(C)~~, deprotecting the a protected derivative of compound of formula (IA).

PG4894USW

14. (Previously Presented) A pharmaceutical composition comprising a compound as defined in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.
15. – 19. (Canceled)
20. (Previously Presented) A pharmaceutical composition comprising a compound as defined in claim 2 in admixture with one or more physiologically acceptable carriers or excipients.
21. – 22. (Canceled).
23. (Previously Presented) A method of treating a subject suffering from acute or chronic pain which comprises administering to said subject an effective amount of a compound as claimed in claim 1.
24. (Previously Presented) The method according to claim 23, wherein said subject is a human.
25. (Previously Presented) A method of treating a subject suffering from dysmenorrhoea which comprises administering to said subject an effective amount of a compound as claimed in claim 1.
26. (Previously Presented) The method according to claim 25, wherein said subject is a human.
27. (Previously Presented) A method of treating a subject suffering from arthritis which comprises administering to said subject an effective amount of a compound as defined in claim 1.
28. (Previously Presented) The method according to claim 27 wherein said arthritis is rheumatoid arthritis.

**PG4894USW**

29. (Previously Presented) The method according to claim 28 wherein said subject is a human.
30. (Previously Presented) A method of treating a subject suffering from osteoarthritis which comprises administering to said subject an effective amount of a compound as defined in claim 1.
31. (Previously Presented) The method according to claim 30 wherein said subject is a human.
32. (Previously Presented) A method of treating a subject suffering from acute or chronic pain which comprises administering to said subject an effective amount of a compound as claimed in claim 2.
33. (Previously Presented) The method according to claim 32, wherein said subject is a human.
34. (Previously Presented) A method of treating a subject suffering from dysmenorrhoea which comprises administering to said subject an effective amount of a compound as claimed in claim 2.
35. (Previously Presented) The method according to claim 34, wherein said subject is a human.
36. (Previously Presented) A method of treating a subject suffering from arthritis which comprises administering to said subject an effective amount of a compound as defined in claim 2.
37. (Previously Presented) The method according to claim 36 wherein said arthritis is rheumatoid arthritis.
38. (Previously Presented) The method according to claim 36 wherein said subject is a human.

**PG4894USW**

39. (Previously Presented) A method of treating a subject suffering from osteoarthritis which comprises administering to said subject an effective amount of a compound as defined in claim 2.
40. (Previously Presented) The method according to claim 39 wherein said subject is a human.
41. (New) The method according to claim 12, further comprising the step of interconverting the compound of formula (I) into another compound of formula (I).
42. (New) The method according to claim 13, further comprising the step of interconverting the compound of formula (IA) into another compound of formula (IA).
43. (New) The method according to claim 23, wherein said pain is lower back pain or neck pain.
44. (New) The method according to claim 23, wherein said pain is non-specific lower back pain.
45. (New) The method according to claim 32, wherein said pain is lower back pain or neck pain.
46. (New) The method according to claim 32, wherein said pain is non-specific lower back pain.